MedTrace Logo

Prognostic Potential of Olfactory Function in Glioblastoma: a Prospective Observational Study

NCT06954636 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 128

Last updated 2025-07-08

No results posted yet for this study

Summary

The study aims to investigate the prognostic significance of olfactory function in patients with glioblastoma. We are examining olfactory function at various points during therapy and correlating the results with survival data. In addition, neurocognitive tests will be carried out to correlate the results of olfactory function with the patient's cognitive abilities. Investigations into the quality of life and psychological condition of the patients are also performed. In addition to the cohort of glioblastoma patients, there is a control cohort without tumor disease in which the olfactory testing is also carried out in order to have a comparison.

Conditions

  • Glioblastoma Multiforme, Adult
  • Glioblastoma or Gliosarcoma
  • Glioblastoma, Adult

Interventions

DIAGNOSTIC_TEST

olfactory testing (threshold and identification test)

In the identification test, 12 sniffin sticks are presented, which the patient has to name using a selection card with four terms each. Both nostrils are tested individually at each visit during the identification test. A correct answer scores one point. A maximum of 12 points is possible. The threshold test consists of 16 dilution levels. Each level contains one sniffin stick with odor and two blanks. All three sniffin sticks of a dilution level are presented to the patient one after the other with eyes closed. The patient must indicate which of the three sticks contains an odor. Depending on whether the patient gives the correct answer, the three sniffin sticks in the next higher or next lower level are presented next. A maximum of 16 points is possible.

Sponsors & Collaborators

  • Münster University Hospital, Germany

    collaborator UNKNOWN

  • Sied Kebir

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-05-03
Primary Completion
2027-12-31
Completion
2028-12-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06954636 on ClinicalTrials.gov